Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Eiger nets $20mm via follow-on

Executive Summary

Eiger BioPharmaceuticals Inc. netted $20mm through the follow-on public offering of 2.1mm common shares (including full exercise of the overallotment) at $10 each. The company will use some of the funds for ongoing development of its four candidates, all of which are in Phase II--ubenimex for lymphedema and hypertension (licensed from Nippon Kayaku), exendin 9-39 for hypoglycemia, pegylated interferon lambda for hepatitis delta virus (from BMS), and Sarasar (lonafarnib) for HDV (from Merck).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies